Therapeutics
Developing Next Generation Therapeutics for Healthy Life
Pipeline
Oncology/Immuno-Oncology
-
Product(Partners)TargetIndicationRegionDiscoveryPreclinicalINDPH1PH2PH3BLA Filing
-
view more
Porustobart HBM4003
CTLA-4
Melanoma, HCC*, RCC* & Other Advanced Solid Tumors
Melanoma, HCC*, NEC/NET* & Other Advanced Solid Tumors
NSCLC* & Other Advanced Solid Tumors
Global
Global
Global
-
view more
HBM7008
B7H4x4-1BB
Solid Tumors
Ex-U.S. 1
-
view more
HBM1020
B7H7
Solid Tumors
Global
-
HBM9033
MSLN ADC
Solid Tumors
Global License to Pfizer
-
HBM1022
CCR8
Solid Tumors
Global
-
HBM1007
CD73
Solid Tumors
Global
-
HBM7022
CLDN18.2xCD3
Solid Tumors
Global License to AstraZeneca
-
HBM9027
PD-L1xCD40
Solid Tumors
Global
-
HBM9014
LIFR
Solid Tumors
Global
-
HBM7004
B7H4×CD3
Solid Tumors
Global
-
HBM1047
CD200R1
Solid Tumors
Global
Immunology
-
Product(Partners)TargetIndicationRegionDiscoveryPreclinicalINDPH1PH2PH3BLA Filing
-
view more
Batoclimab HBM9161(HanAll)
FcRn
MG*
TED*
Greater China License to CSPC
Greater China License to CSPC
-
HBM9378
TSLP
Asthma
Global
-
HBM
-
Partner
-
Registrational Clinical Trial
-
Monotherapy
-
PD1 / Chemo
-
Breakthrough Therapy Designation
* HCC = Hepatocellular Carcinoma
* RCC = Renal Cell Carcinoma
* NEC = Neuroendocrine Carcinoma
* NET = Neuroendocrine Tumour
* NSCLC = Non-Small Cell Lung Cancer
* MG = Myasthenia Gravis
* TED = Thyroid Eye Disease
* The U.S. rights of HBM7008 is out-licensed to Cullinan Oncology in February 2023
Publications
-
Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models
-
High throughput identification of human monoclonal antibodies and heavy-chain-only antibodies to treat snakebite
-
WNT/beta-catenin signalling interrupts a senescence-induction cascade in human mesenchymal stem cells that restricts their expansion
-
TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China
-
An anti-CTLA-4 heavy chain-only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile
-
A phase I study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma
-
Innovative B7H4 x CD3 & B7H4 x 4-1BB bispecifics for solid tumor therapies
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers
-
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
-
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
-
A human monoclonal antibody blocking SARS-CoV-2 infection
-
SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model
-
Cell Engager Summit Exclusive Speaker Interview
-
Therapeutic response and possible biomarkers in acute attacks of neuromyelitis optica spectrum disorders: a prospective observational study
-
Preclinical evaluation of HBM7022, an HBICE™ 2+1 CLDN18.2 x CD3 bispecific antibody, for gastric cancer
-
Development of fully human T-cell engaging bispecific antibodies targeting B7H4
-
Discovery of potent and functional human antibodies against a new B7-family member, B7H7, for cancer immunotherapy
-
Multimeric single-domain antibody complexes protect against bunyavirus infections
-
HCAb based bispecific immune cell engager (HBICE) platform enables fast and convenient generation of the next generation bispecific antibodies with high potency, promising safety profiles and excellent developability
-
HBM1022, a novel anti-CCR8 antibody, depletes tumor-infiltrating regulatory T cells via enhanced ADCC activity, mediates potent anti-tumor activity
-
Novel monoclonal antibodies (mAbs) targeting human CCR8 provide potential candidates for next generation cancer immunotherapy
-
HBM1007 – A highly potent anti-CD73 mAb candidate for mono and combination IO therapy
-
BCMA x CD3 bispecific antibody – a novel HBICE™-based molecule with efficient tumor killing and minimal cytokine release
-
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
-
A new generation of fully human anti-CTLA-4 heavy chain only antibody
-
A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity
Copyright © 2022 Harbour BioMed. All Rights Reserved 沪ICP备19015946号-1